Form 4: Dyne Therapeutics Director Dirk Kersten Sells Shares in Multiple Transactions

Director Dirk Kersten reports selling shares of Dyne Therapeutics (DYN) on September 18 and 19, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Dirk Kersten, a director of Dyne Therapeutics, reported the sale of common stock on September 18 and 19, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (FCF IV) on April 9, 2024.
• On September 18, 2024, 1,554 shares were sold at a weighted average price of $35.03, with individual prices ranging from $35.00 to $35.09.
• On September 19, 2024, two transactions occurred: 27,767 shares were sold at a weighted average price of $35.74 (ranging from $35.06 to $36.058), and 50,972 shares were sold at a weighted average price of $36.41 (ranging from $36.06 to $37.03).
• Following these transactions, Dirk Kersten directly owns 313,538 shares and indirectly owns 5,795,364 shares through Forbion Capital Fund IV Cooperatief U.A. and ForDyne B.V.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.

Risks

• The sales by a director could be perceived negatively by investors, although they were conducted under a pre-arranged trading plan.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, or any individuals owning more than 10% of a company's shares) buy or sell their company's stock. These filings provide transparency to the market regarding insider transactions.

Comparison to Industry Standards

• Insider sales are a common occurrence in publicly traded companies.
• The use of Rule 10b5-1 trading plans is a standard practice to allow insiders to sell shares without being accused of trading on non-public information.
• The size of the transactions is relatively small compared to the overall holdings of the reporting person.

Stakeholder Impact

• The transactions may have a minor impact on shareholders' perception of the company, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates